Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ensem Therapeutics
Seagen Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Kivu Bioscience Inc.
STORM Therapeutics LTD
Eli Lilly and Company
Terremoto Biosciences Inc.
Jazz Pharmaceuticals
Kaiser Permanente
AstraZeneca
Seagen Inc.
Duke University
Radiopharm Theranostics, Ltd
Arvinas Inc.
Tizona Therapeutics, Inc
Dana-Farber Cancer Institute
Normunity AccelCo, Inc.
IDEAYA Biosciences
MacroGenics
University of Oklahoma
SystImmune Inc.
Daiichi Sankyo
Solve Therapeutics
University of Nebraska
Adela, Inc
Radiopharm Theranostics, Ltd
Second Life Therapeutics
Elephas
Fusion Pharmaceuticals Inc.
Elephas
GlaxoSmithKline
Fate Therapeutics
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
West China Hospital
Volastra Therapeutics, Inc.
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
LigaChem Biosciences, Inc.
Merck Sharp & Dohme LLC
Bolt Biotherapeutics, Inc.
Tempest Therapeutics
Guardant Health, Inc.
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC